Details

Autor(en) / Beteiligte

• Kelly, Jacob P., MD
• Mentz, Robert J., MD
• Mebazaa, Alexandre, MD
• Voors, Adriaan A., MD
• Butler, Javed, MD, MPH
• Roessig, Lothar, MD
• Fiuzat, Mona, PharmD
• Zannad, Faiez, MD
• Pitt, Bertram, MD
• O’Connor, Christopher M., MD
• Lam, Carolyn S.P., MBBS

Titel

Patient Selection in Heart Failure With Preserved Ejection Fraction Clinical Trials

Ist Teil von

• Journal of the American College of Cardiology, 2015-04, Vol.65 (16), p.1668-1682

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2015

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Abstract Recent clinical trials in patients with heart failure with preserved ejection fraction (HFpEF) have provided important insights into participant selection strategies. Historically, HFpEF trials have included patients with relatively preserved left ventricular ejection fraction ranging from 40% to 55% and a clinical history of heart failure. Contemporary HFpEF trials have also incorporated inclusion criteria such as hospitalization for HFpEF, altered functional capacity, cardiac structural and functional abnormalities, and abnormalities in neurohormonal status (e.g., elevated natriuretic peptide levels). Careful analyses of the effect of these patient selection criteria on outcomes in prior trials provide valuable lessons for future trial design. We review recent and ongoing HFpEF clinical trials from a patient selection perspective and appraise trial patient selection methodologies in relation to outcomes. This review reflects discussions between clinicians, scientists, trialists, regulators, and regulatory representatives at the 10th Global CardioVascular Clinical Trialists Forum in Paris, France, on December 6, 2013.